

# Chapter 2

## Risk Factors and Screening for Colorectal Cancer

Joseph C. Anderson

**Keywords** Risk factors • Tobacco use • Body mass index

Screening for colorectal cancer (CRC) involves consideration of only a patient's age and their family history of CRC [1, 2], but there are other risk factors which can potentially affect screening. This section will examine known risk factors and how some of these can affect one's risk and subsequent screening for CRC. Other factors such as personal and family history of colorectal neoplasia as well as aspirin and other chemo-preventative agents will be discussed elsewhere. This section will serve as an overview of the various factors and the respective studies that examine their association with CRC as well as advanced adenomas. Age has been shown to be one of the strongest predictors of CRC [3] and will not be discussed as there is little debate as to the importance of this factor. In addition, this chapter will examine the modifiable risk factors since this is where clinicians can help patients to reduce their risk of CRC. A study by Platz et al. demonstrated that over two thirds of CRC may be preventable in men [4].

### Prospective Studies

We will also review the four large prospective studies that examined risk factors and CRC. Table 2.1 shows the salient results of these large trials, and the details will be discussed in the subsequent sections. These include the Cancer Prevention Study II (CPS-II), which is a prospective cohort study funded and conducted by the American Cancer Society (ACS). The goal of the study is to examine the impact of environmental and lifestyle factors on cancer etiology in a large group of American men and

---

J.C. Anderson (✉)

Division of Gastroenterology, University of Connecticut Health Center, Colon Cancer Prevention Program, Farmington, CT 06030-1845, USA  
e-mail: joanderson@uchc.edu

**Table 2.1** Results of selected prospective longitudinal studies

	Smoking	Red meat	Alcohol	Obesity	Physical activity	Fiber	Diabetes mellitus
Cancer prevention Study II	↑ CRC	↑ Distal cancer	–	↑ Risk for WHR and BMI	↓ Colon but not rectal cancer	↑ CRC Intake fruit/veg ↑ CRC	↑ Men and ↔ women
Nurse's Health Study	↑ CRC after 35 years	↑ Colon but not rectal cancer	↑ Colon but not rectal	↑ CRC 1.5 X women w/ BMI<21	↓ >21 MET's/week	↔	↑ But ↔ for HbA1c
HPFS	↑ CRC after 35 years	↑ For 5 servings/ week	↑ CRC > 15g/day	↑ BMI> 22.5, 29.5% of CRC attributed to this increase	↓ > 27 METS/week	↔	–
EPIC	↑ In proximal CRC in ever smokers	↑ Red meat but ↓ fish	↑ Highest risk in rectum	↑ With WHR	↓ for right sided cancer	↓ Especially distal CRC	↑ Risk for HbA1c

↑ Arrows refer to risk for CRC except where indicated

women [5]. Study participants (known as the CPS-II Baseline Cohort) completed an initial study questionnaire in 1982 that obtained information on a range of lifestyle factors such as diet, use of alcohol and tobacco, occupation, medical history, and family cancer history. Cause of death has been documented for 99% of all deaths that have occurred. The CPS-II Nutrition Cohort is a subgroup of 184,194 men and women who were mailed additional questionnaires in 1997, 1999, 2001, 2003, 2005, and 2007, to update exposure information and to obtain self-reported cancer diagnoses. The European Prospective Investigation into Cancer (EPIC) was set up to examine the association between diet, nutritional status, lifestyle and environmental factors, and the incidence of cancer. EPIC has recruited over half a million people in ten European countries: Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, and the United Kingdom [6]. The Health Professionals Follow-Up Study (HPFS) was started in 1986 by Walter Willett and Meir Stampfer [7] and has enrolled 51,529 men. The HPFS is sponsored by the Harvard School of Public Health and is funded by the National Heart, Lung, and Blood Institute and National Cancer Institute. The Nurses' Health Study (NHS) is designed to complement the HPFS and consists of a similar number of women [8].

## Risk Factors

### *Red Meat*

Red meat, in the form of beef or lamb, has been examined as a risk factor in many case control and longitudinal population studies. In most of these studies, consumption of red meat is associated with an increased risk for CRC. A recent longitudinal study from Europe, the EPIC, demonstrated an increased risk for people who consumed more than 160 g of red or processed meat per day [9]. In another prospective study from the United States, the HPFS, there was an increased risk of approximately threefold for those who consumed more than five servings per week of red meat. The comparison group ate less than one serving per month. In a study that combined the NHS and the HPFS, red meat was a risk for colon but not rectal cancer [3]. In the CPS II Nutrition Cohort, Chao et al. observed an increased risk of red meat for distal and rectal CRC [10].

There are many hypotheses regarding the increased risk from red meat, which include an increased fat consumption, increased heme absorption, and stimulation of insulin secretion. Furthermore, there are data to indicate that increased cooking time may be associated with an increased risk [11, 12] due to the increased production of heterocyclic amines [13]. In addition, how these meats are processed in the patients may also be important. A recent study NHS demonstrated that those women with a faster acetylation of the carcinogens from red meat had an increased risk of CRC [14]. With regard to the risk from fat in red meat, many studies have disputed this risk [15–17]. Regardless of the mechanism, it appears that regular consumption of meat, especially if it is cooked well, increases the risk for CRC.

## ***Fiber Intake***

Fiber, especially in the form of fruits and vegetables, has been considered beneficial in helping to lower one's risk for CRC [18–20]. Proposed mechanisms regarding the benefit from fiber include increased folic acid consumption, increased binding of carcinogens, lower colonic pH, decreased colonic transit time, an increased production of short chain fatty acids as well as micronutrients found in vegetables including anti-oxidants [21, 22]. However, results of randomized controlled studies using fiber in the form of fruits and vegetables [23] or cereal did not lower the risk of colorectal adenomas [24]. These studies contradict previous data demonstrating a decreased risk of colorectal neoplasia associated with fiber consumption. The majority of case control studies have demonstrated a benefit with a meta-analysis of 16 case control trials showing an approximately 50% reduction in CRC from fiber consumption [25]. With regard to prospective studies, the results have been mixed. While the EPIC trial demonstrated a reduction of 40% in CRC incidence in patients who consumed the most fiber [26], the NHS showed no difference in colorectal neoplasia risk in those who consumed fiber [27]. One study combining the NHS and HPFS showed no effect of fruit and vegetable consumption on CRC [28]. A more recent analysis of the EPIC trial showed similar results, but there was a positive association between fruit and vegetable intake and current smokers [29]. However in the CPS-II, risk of fatal colon cancer decreased with more frequent consumption of vegetables and high-fiber grains [30]. A more recent analysis of the CPS-II showed that men and women with low intake of fruit and vegetable increased the risk for CRC, but a higher intake did not offer protection [31]. In summary, the benefit from fruits and vegetables with respect to lowering the risk for CRC is still in question.

## ***Physical Exertion***

It has been hypothesized that increased physical activity may decrease the risk for CRC by reducing body mass, decreasing colonic transit time, better glucose tolerance, and lower insulin levels [32, 33]. One case control study from Kaiser Permanente in Northern California, Utah, and Minnesota observed that those patients with a high Body Mass Index and low physical activity had the highest risk for CRC [34]. Results from the CPS-II, a prospective mortality study of over 700,000 patients, showed an association between physical activity and lower risk for death from CRC [30]. Data from the HPFS showed a significant reduction in risk for CRC in men who had the most physical activity vs. those who had the least [35]. This dose-related effect was evident in the results of a meta-analysis of 52 patients, which demonstrated an inverse relationship between level of physical activity and risk for CRC in men and women [36]. A more recent analysis of the HPFS showed that men who engaged in more than 27 MET hours per week of physical activity had a lower adjusted hazard ratio for CRC-related death than men

who had 3 MET hours or less ( $HR=0.47$ , 95% confidence interval, 0.24–0.92) [37]. An analysis from the NHS showed a similar protective effect of exercise and CRC reduction in women [38]. Data from the EPIC study reduced the risk for right-sided cancers in lean participants but had no effect on rectal cancer [39]. Chao et al. observed in the CPS-II Nutrition Cohort that recreational physical activity reduced the risk for colon cancer as well as rectal cancer in older men and women [40]. Thus, there appears good evidence to suggest that physical exercise can lower the risk for CRC as well as the mortality associated with the disease.

## ***Gender***

Although most studies have observed an increased risk for men with regard to advanced colorectal neoplasia as well as CRC, the overall lifetime risk for CRC for men and women is numerically similar [41, 42]. In addition, women have a 5-year lag with respect to incidence of CRC. For example, a woman at 55 has a similar risk to a man at 50 years of age [43]. With regard to the risk for CRC, Nguyen et al. in a meta-analysis observed a twofold increase risk for CRC and advanced adenomas in men as compared to women [44]. Furthermore, in the CONCeRN trial, Schoenfeld et al. observed a lower risk for advanced adenomas in women compared to men [45]. A study by Bressler et al. showed that women were more likely than men to have subsequent CRC after having a colonoscopy [46]. Thus it appears that changes with respect to how we screen women as compared to men may be reasonable. More data, however, is needed to explain the paradox of different advanced adenoma rates but similar CRC rates for the genders.

## ***Alcohol***

Ethanol-based beverages have been thought to increase the risk of rectal and colon cancer through a variety of mechanisms including abnormal DNA methylation and repair, induce cytochrome p450 enzymes to increase carcinogen production and alter bile acid composition [47, 48]. An analysis from the HPFS showed that there was a positive correlation between risk of CRC and alcohol in men [49]. This risk increased after 15 g per day which is about one drink per day. In a study that combined the NHS and HPFS, alcohol increased the risk of colon but not rectal cancer [3]. Data from the EPIC trial demonstrated that after controlling for smoking and other known risk factors, alcohol increased the risk of CRC [50]. However in a sub population of the EPIC study, Park et al. observed no risk association between alcohol and CRC [51]. They did find a decrease in risk associated with wine. A study, which combined eight studies for a total of a half a million patients, observed an increased risk for patients who had more than two alcohol beverages per day [52]. In that study, all forms of alcohol increased risk including wine. However, overall it appears that regular alcohol consumption may be associated with an increased risk for CRC and that moderation of alcohol beverage intake may be the best strategy.

## ***Tobacco***

Tobacco exposure, most commonly in the form of cigarette smoking, has only been recognized recently as an important risk for CRC in both men and women. The lag in association may be due to two factors [53]. The first is that it may take up to 35 years of exposure to tobacco to increase the risk of CRC [54, 55]. Second, the increase in smoking among men and women may coincide with the two world wars respectively. Since the earliest reports which included analyses of adenoma risk [56], there have been numerous case control [57, 58] and population studies [59–62] that demonstrate the increased risk associated with smoking. Smoking is now considered to be a risk, which is responsible for 20% of all CRC in the United States [63]. Several studies report a 30% increase risk for colon and rectal cancer for male and female smokers [54, 55, 57, 62, 64] as well as an increase of up to 50% in deaths from CRC [60, 65].

An important observation that underscores the importance for screening smokers earlier is the younger age at which smokers are diagnosed with CRC. Although there may be other factors that explain this observation, an age difference of at least 5 years between smokers and nonsmokers has been noted in four separate populations over 2 decades [42, 66, 67]. Smokers may also be more likely to present with an advanced stage of CRC than nonsmokers [68]. Furthermore, smokers have perceptions which may decrease their likelihood to be screened [69, 70]. Thus focusing on smokers as a high risk group may aid in increasing screening in a population that is at risk but may be reluctant to receive appropriate testing.

## ***Obesity***

Several studies have demonstrated that obesity increases the risk of CRC in men [35, 71–75] and women [71–73, 75], although this association appears to be stronger in males. In a study examining the HPFS, the men with the highest BMI had a twofold increase risk for CRC as compared to the thinnest men [35]. For women in NHS, the risk for obese women was 1.5 times that of their thinner counterparts [38]. In the CPS-II Nutrition Cohort, there was a correlation between increased waist circumference and CRC [76]. In the EPIC trial, waist to hip ratio and waist circumference, indicators of abdominal obesity, were positively correlated with the risk for CRC [77]. Obesity is a strong risk factor for type 2 diabetes mellitus; a probable independent risk factor for CRC [78]. This association also appears to be stronger for men [79]. Hyperglycemia [80–82], hyperinsulinemia [83], and elevated levels of free insulin-like growth factor (IGF-1) [84] have tumor-promoting properties [85–87]. Carcinogenesis may result from insulin resistance leading to increased cellular proliferation and reduced apoptosis [85, 88, 89].

The identification of BMI as a risk factor for CRC is important for many reasons, especially in light of the increasing prevalence of obesity in the United States [90]. While there are many reasons for health care providers to promote good health, the

possibility of reducing the risk of colorectal neoplasia with weight loss [91] and the implication of an increased risk of cancer represent one further reason to counsel patients regarding weight reduction. Current guidelines recommend colonoscopic screening every 10 years beginning at age 50 for healthy, low risk individuals. However obese women have been shown to be less likely to have colon cancer screening [92]. Obesity may represent a risk that justifies beginning screening at an earlier age in order to reduce the progression of colorectal polyps to cancer [2].

## ***Diabetes Mellitus***

The risk of CRC associated with type II diabetes mellitus is important given the anticipated prevalence of type II diabetes by 2030, which will be over one third of a billion [93, 94]. In the Breast Cancer Detection Demonstration Project (BCDDP), women with diabetes had an over 1.5-fold increase risk for CRC than non-diabetics [95]. The risk for CRC associated with diabetes has been shown in large case control studies [96, 97] as well as a prospective study of women [98]. There are many hypotheses regarding the pathogenesis of CRC in diabetics, which include endogenous insulin, exogenous insulin [99], insulin growth factors, and glucagon-like peptide-1 [100]. The hyperinsulinemia theory is based on the premise that elevated levels of insulin and free IGF-1 promote growth of the number of colon cells and lead to a survival benefit of transformed cells, ultimately resulting in CRC [101]. An analysis of the CPS-II Nutrition Cohort showed an association between CRC and diabetes in men but not women [102]. Data from the NHS showed a direct correlation between CRC and a diagnosis of diabetes mellitus [103]. Data from the EPIC study demonstrated that increasing glycated hemoglobin was a risk for women but not men [104]. However, in the Norfolk sample of the EPIC study, patients with Diabetes Mellitus had a threefold increased risk of CRC [105]. In this study, there was direct correlation between risk and glycated hemoglobin. In an analysis of the NHS, there was no association between glycated hemoglobin and CRC [106].

## ***Race***

CRC rates are the highest for African Americans for both incidence [107] as well as overall mortality [108] when compared to white patients of both genders. The authors of a recent study hypothesized that the reasons for these differences may be related to etiologic factors such as smoking or diabetes mellitus or the decreased use of screening and diagnostic examinations among African Americans [107]. Alexander et al. conducted an exhaustive review of studies from SEER and population-based cancer registries, Veterans Affairs (VA) databases, healthcare coverage databases, and university and other medical center data sources [109]. In this review,

they observed an increase in stage-specific risks of CRC mortality as well as a shorter survival for African Americans compared with Caucasians. The biggest disparities were observed in university and non-VA hospital-based medical center studies, while a smaller discrepancy was evident in VA-based studies. They concluded that an advanced stage is responsible for the increased mortality. Laiyemo et al. concluded that the difference in mortality may be related more in access to screening rather than biology. In their analysis of data from the PLCO trial, they observed that when compared with whites, blacks were less likely to have a diagnostic test (adjusted risk ratio=0.88, 95% confidence interval=0.83–0.93). There was no statistically significant difference between blacks and whites with regard to the prevalence of adenomas, advanced adenomas, or CRC [110]. Agrawal et al. presented a rationale for screening African Americans at the age of 45 years [111]. They cited the increased incidence and mortality, a younger age of CRC diagnosis, a more proximal colonic distribution of cancers and adenomas in, and a decreased utilization of diagnostic testing and screening for CRC in African Americans compared to whites.

## Asymptomatic Screening Populations

Cross-sectional studies of asymptomatic screening populations can yield important data regarding the relative strengths of various CRC risk factors [112–114]. Large studies, which often involve symptomatic patients, cannot provide data on prevalence. Unlike studies relying on second hand data or self-report, cross-sectional studies performed in gastrointestinal suites offer the added advantage of accurate and complete endoscopic evaluation of all patients. This ensures that controls have no polyps. An example of this may be found in the risk of smoking and colorectal neoplasia. The risk of tobacco exposure in two screening population was twofold with respect to the risk for advanced neoplasia [112, 114, 115]. The magnitude of this increased risk for adenomas was confirmed in a meta-analysis published recently, which observed an Odds Ratio of 1.82 for people who had ever smoked and 2.14 for current smokers [116]. However, the risk associated with CRC was significantly less in a meta-analysis of 106 observational studies (OR=1.25) [117]. The authors hypothesized that the difference may be due to the fact that many of the studies examining CRC are based on large population studies, which may have a limitation with respect to the evaluation of controls. Specifically, since the controls may not be endoscoped, there is no way of ensuring that they are neoplasia free with regard to adenocarcinoma or advanced neoplasia. This limitation may blunt the observed risk associated with smoking. In addition, in large population studies, there is often no distinction between those who were diagnosed and those who were screened for CRC. When the authors examined the trials in which controls were endoscoped, the risk for CRC was higher for smokers.

Another advantage of cross-sectional studies is that they can examine risk factors that may be associated with a recent trend. A good example of this is smoking, which



was identified as a risk for colorectal neoplasia in patients with adenomas prior to those with adenocarcinoma [53]. Another example may be obesity, which has been increasing in prevalence. Although a gender difference has been observed in advanced adenomas, there has been consensus in the positive association between obesity and CRC in men and women. With regard to advanced neoplasia, there has been an increased risk for women and no association in men [114, 118, 119].

In addition, since the cross-sectional studies in asymptomatic populations allow for a complete endoscopic evaluation of the enrolled patients. This allows for examination of anatomic location of polyps as well as the morphology. These aspects allowed for the identification, for example, of smoking as a risk for patients with isolated advanced neoplasia [120] as well as patients with flat neoplasia [121]. Finally, since the goal of screening for CRC with colonoscopy is prevention through identification and removal of advanced adenomas [2], identifying risk factors for these lesions may be as important as identifying risks for CRC.

## Translation into Screening

### *Models*

One of the concepts behind the strategy for individualizing CRC screening is to utilize the resources for patients that will benefit the most from these tests. Furthermore, guidelines for CRC screening recommend that patients without a family history of CRC be screened at the age of 50 with a colonoscopy. There has been a concern regarding the possibility of insufficient resources to screen all eligible patients with colonoscopy [122]. One author has suggested that perhaps there may be alternative strategies such as a sigmoidoscopy as a first step and a colonoscopy at a later age [123]. Another author has suggested that perhaps CRC screening commence for different risk groups at different ages [43]. He identified gender as a potential variable since women may lag men by 5 years with respect to their risk for colorectal neoplasia. Thus the development of models may be useful in triaging patients.

Most models have used CRC risk factors in developing the risk assessments. Betes et al. used age, gender, and BMI in their model for advanced neoplasia [124]. Kim et al. validated a model based on data from the NHS and HPFS [125, 126]. In that model, they used BMI, vegetable intake, red meat consumption, physical activity, and alcohol intake in addition to other known risk factors such as multivitamin and aspirin use. Driver et al. developed a model predicting the risk for CRC in men based on the 21,581 United States male physicians in the Physician's Health Study [127]. In that model, points were assigned based on strength of risk for each variable. The model included 2 points for every decade over 50, 1 point for history of smoking, 1 point for BMI 25–29.9, 2 points for BMI  $\geq 30$ , and 1 point for drinking alcohol once or more per week.

Freedman et al. developed a model which examined the risk for CRC by anatomical subsite, proximal vs. distal, for white men and women [128]. For men, personal history of colorectal neoplasia, family history of CRC, not using aspirin, smoking, consuming <5 servings of vegetables per day, and higher BMI were associated with an increased risk for proximal CRC. For distal CRC in men, the same variables except smoking and lower vegetables were associated with an increased risk. For women proximally having personal history of colorectal neoplasia, family history of CRC, not using aspirin, no regular physical activity, consuming <5 servings of vegetables per day, and negative estrogen status were associated with an increased risk. For distal CRC in women, a personal history of colorectal neoplasia, family history of CRC, not using aspirin, higher BMI, older age, and estrogen negative status increase the risk.

On the National Cancer Institute web site (<http://cisnet.cancer.gov/projections/colorectal/>), there is an interactive model with risk factors based on Health People 2010. Included in the model are smoking status (yes/no), obesity (based on body mass index (BMI)), physical activity (met-hours per week), fruit and vegetable intake (servings per day), multivitamin use (yes/no), red meat intake (servings per day as a main dish), and aspirin and HRT use. The model uses data from the Nurses Health Study (NHS) and the HPFS to estimate the effect of risk factors on CRC [129].

## ***Screening Guidelines***

The American College of Gastroenterology recently published guidelines on which they recommend that African Americans begin screening at the age of 45 years [2]. In addition, they identified people who smoke and those who are obese as populations who require special attention from practitioners. They tempered their recommendation that these patients be screened earlier by adding that these patients may have comorbidities that may reduce the benefit from screening. These are the first guidelines regarding CRC screening to consider factors other than age and family history of CRC when forming a screening paradigm.

## ***New Problems in Screening***

One of the biggest problems facing endoscopists is the proximal colon and the lack of effectiveness of colonoscopy in reducing the risk for advanced colorectal neoplasia [130, 131]. There have been many hypotheses regarding an explanation for this observation. One plausible answer may lie in the serrated pathway that is associated with BRAF and methylation abnormalities, which may account for a large percentage of interval cancers [132, 133], or those lesions that are diagnosed between scheduled colonoscopy surveillance. Serrated polyps are often proximal and associated with synchronous advanced colorectal lesions [134]. Since smokers often have cancers that

are located in the rectum and proximal colon where serrated lesions are often found, one expert has suggested that smoking may be associated with serrated histology. Recently, a trial examining aberrant crypt foci observed an association between serrated histology and smoking [135]. In addition, there was a study demonstrating a higher rate of flat adenomas in smokers [121]. In addition, Anderson et al. identified smoking as a risk for sessile serrated adenomas [136]. Thus, smokers may be at higher risk for lesions that may be difficult to detect and may require special techniques for screening. This is a good example of incorporating risk factors into a screening algorithm.

## References

1. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology*. 2008;134:1570–95.
2. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol*. 2009;104:739–50.
3. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. *Int J Cancer*. 2004;108:433–42.
4. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. *Cancer Causes Control*. 2000;11:579–88.
5. <http://www.cancer.org/Research/ResearchProgramsFunding/cancer-prevention-study-overviews>, 2010.
6. <http://epic.iarc.fr/about.php>.
7. [http://www.hsph.harvard.edu/hpfs/hpfs\\_about.htm](http://www.hsph.harvard.edu/hpfs/hpfs_about.htm).
8. <http://www.channing.harvard.edu/nhs/index.php/history/>.
9. Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. *J Natl Cancer Inst*. 2005;97:906–16.
10. Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, et al. Meat consumption and risk of colorectal cancer. *JAMA*. 2005;293:172–82.
11. Gerhardtsson de Verdier M, Hagman U, Peters RK, Steineck G, Overvik E. Meat, cooking methods and colorectal cancer: a case-referent study in Stockholm. *Int J Cancer*. 1991;49:520–5.
12. Martinez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, et al. Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. *Carcinogenesis*. 2007;28:2019–27.
13. Gunter MJ, Probst-Hensch NM, Cortessis VK, Kulldorff M, Haile RW, Sinha R. Meat intake, cooking-related mutagens and risk of colorectal adenoma in a sigmoidoscopy-based case-control study. *Carcinogenesis*. 2005;26:637–42.
14. Chan AT, Tranah GJ, Giovannucci EL, Willett WC, Hunter DJ, Fuchs CS. Prospective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. *Int J Cancer*. 2005;115:648–52.
15. Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). *Cancer Causes Control*. 1994;5:38–52.

16. Goldbohm RA, van den Brandt PA, van 't Veer P, Brants HA, Dorant E, Sturmans F, et al. A prospective cohort study on the relation between meat consumption and the risk of colon cancer. *Cancer Res.* 1994;54:718–23.
17. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. *N Engl J Med.* 1990;323:1664–72.
18. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. *Cancer Res.* 1994;54:2390–7.
19. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. *Ann Intern Med.* 1998;129:517–24.
20. Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. *Cancer Epidemiol Biomarkers Prev.* 1998;7:163–8.
21. Kritchevsky D. Epidemiology of fibre, resistant starch and colorectal cancer. *Eur J Cancer Prev.* 1995;4:345–52.
22. Potter JD. Colorectal cancer: molecules and populations. *J Natl Cancer Inst.* 1999;91:916–32.
23. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. *N Engl J Med.* 2000;342:1149–55.
24. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. *N Engl J Med.* 2000;342:1156–62.
25. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. *J Natl Cancer Inst.* 1990;82:650–61.
26. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. *Lancet.* 2003;361:1496–501.
27. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. *N Engl J Med.* 1999;340:169–76.
28. Michels KB, Edward G, Joshupura KJ, Rosner BA, Stampfer MJ, Fuchs CS, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. *J Natl Cancer Inst.* 2000;92:1740–52.
29. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, et al. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr.* 2009;89:1441–52.
30. Thun MJ, Calle EE, Namboodiri MM, Flanders WD, Coates RJ, Byers T, et al. Risk factors for fatal colon cancer in a large prospective study. *J Natl Cancer Inst.* 1992;84:1491–500.
31. McCullough ML, Robertson AS, Chao A, Jacobs EJ, Stampfer MJ, Jacobs DR, et al. A prospective study of whole grains, fruits, vegetables and colon cancer risk. *Cancer Causes Control.* 2003;14:959–70.
32. Dowse GK, Zimmet PZ, Gareeboo H, George K, Alberti MM, Tuomilehto J, et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. *Diabetes Care.* 1991;14:271–82.
33. Regensteiner JG, Mayer EJ, Shetterly SM, Eckel RH, Haskell WL, Marshall JA, et al. Relationship between habitual physical activity and insulin levels among nondiabetic men and women. San Luis Valley Diabetes Study. *Diabetes Care.* 1991;14:1066–74.
34. Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN, et al. Energy balance and colon cancer—beyond physical activity. *Cancer Res.* 1997;57:75–80.
35. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. *Ann Intern Med.* 1995;122:327–34.
36. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. *Br J Cancer.* 2009;100:611–6.

37. Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, et al. Physical activity and male colorectal cancer survival. *Arch Intern Med.* 2009;169:2102–8.
38. Martinez ME, Giovannucci E, Spiegelman D, Hunter DJ, Willett WC, Colditz GA. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. *J Natl Cancer Inst.* 1997;89:948–55.
39. Friedenreich C, Norat T, Steindorf K, Boutron-Ruault MC, Pischon T, Mazuir M, et al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2006;15:2398–407.
40. Chao A, Connell CJ, Jacobs EJ, McCullough ML, Patel AV, Calle EE, et al. Amount, type, and timing of recreational physical activity in relation to colon and rectal cancer in older adults: the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev.* 2004;13:2187–95.
41. Roy HK, Bianchi LK. Differences in colon adenomas and carcinomas among women and men: potential clinical implications. *JAMA.* 2009;302:1696–7.
42. Zisman AL, Nickolov A, Brand RE, Gorchow A, Roy HK. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. *Arch Intern Med.* 2006;166:629–34.
43. Lieberman D. Race, gender, and colorectal cancer screening. *Am J Gastroenterol.* 2005;100:2756–8.
44. Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2009;7:676–81.
45. Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. *N Engl J Med.* 2005;352:2061–8.
46. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. *Gastroenterology.* 2007;132:96–102.
47. Choi SW, Stickel F, Baik HW, Kim YI, Seitz HK, Mason JB. Chronic alcohol consumption induces genomic but not p53-specific DNA hypomethylation in rat colon. *J Nutr.* 1999;129:1945–50.
48. Kune GA, Vitetta L. Alcohol consumption and the etiology of colorectal cancer: a review of the scientific evidence from 1957 to 1991. *Nutr Cancer.* 1992;18:97–111.
49. Thygesen LC, Wu K, Gronbaek M, Fuchs CS, Willett WC, Giovannucci E. Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. *Epidemiology.* 2008;19:258–64.
50. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer.* 2007;121:2065–72.
51. Park JY, Mitrou PN, Dahm CC, Luben RN, Wareham NJ, Khaw KT, et al. Baseline alcohol consumption, type of alcoholic beverage and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition-Norfolk study. *Cancer Epidemiol.* 2009;33:347–54.
52. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. *Ann Intern Med.* 2004;140:603–13.
53. Giovannucci E. Should smokers be considered a high-risk group for colorectal cancer? *Dig Liver Dis.* 2004;36:643–5.
54. Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. *J Natl Cancer Inst.* 1994;86:192–9.
55. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Kearney J, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. *J Natl Cancer Inst.* 1994;86:183–91.
56. Zahm SH, Cocco P, Blair A. Tobacco smoking as a risk factor for colon polyps. *Am J Public Health.* 1991;81:846–9.

57. Newcomb PA, Storer BE, Marcus PM. Cigarette smoking in relation to risk of large bowel cancer in women. *Cancer Res.* 1995;55:4906–9.
58. Verla-Tebit E, Lilla C, Hoffmeister M, Brenner H, Chang-Claude J. Cigarette smoking and colorectal cancer risk in Germany: a population-based case-control study. *Int J Cancer.* 2006;119:630–5.
59. Akhter M, Nishino Y, Nakaya N, Kurashima K, Sato Y, Kuriyama S, et al. Cigarette smoking and the risk of colorectal cancer among men: a prospective study in Japan. *Eur J Cancer Prev.* 2007;16:102–7.
60. Chao A, Thun MJ, Jacobs EJ, Henley SJ, Rodriguez C, Calle EE. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. *J Natl Cancer Inst.* 2000;92:1888–96.
61. Limburg PJ, Vierkant RA, Cerhan JR, Yang P, Lazovich D, Potter JD, et al. Cigarette smoking and colorectal cancer: long-term, subsite-specific risks in a cohort study of post-menopausal women. *Clin Gastroenterol Hepatol.* 2003;1:202–10.
62. Paskett ED, Reeves KW, Rohan TE, Allison MA, Williams CD, Messina CR, et al. Association between cigarette smoking and colorectal cancer in the Women's Health Initiative. *J Natl Cancer Inst.* 2007;99:1729–35.
63. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev.* 2001;10:725–31.
64. Leufkens AM, Van Duijnhoven FJ, Siersema PD, Boshuizen HC, Vrieling A, Agudo A, et al. Cigarette smoking and colorectal cancer risk in the European prospective investigation into cancer and nutrition study. *Clin Gastroenterol Hepatol.* 2011;9:137–44.
65. Colangelo LA, Gapstur SM, Gann PH, Dyer AR. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. *Cancer.* 2004;100:288–93.
66. Buc E, Kwiatkowski F, Alves A, Panis Y, Mantion G, Slim K. Tobacco smoking: a factor of early onset of colorectal cancer. *Dis Colon Rectum.* 2006;49:1893–6.
67. Michalek AM, Cummings KM. The association between cigarette smoking and age at cancer diagnosis. *Hum Biol.* 1987;59:631–9.
68. Campbell RJ, Ferrante JM, Gonzalez EC, Roetzheim RG, Pal N, Herold A. Predictors of advanced stage colorectal cancer diagnosis: results of a population-based study. *Cancer Detect Prev.* 2001;25:430–8.
69. Coups EJ, Manne SL, Meropol NJ, Weinberg DS. Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. *Cancer Epidemiol Biomarkers Prev.* 2007;16:510–6.
70. Messina CR, Kabat GC, Lane DS. Perceptions of risk factors for breast cancer and attitudes toward mammography among women who are current, ex- and non-smokers. *Women Health.* 2002;36:65–82.
71. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. *World J Gastroenterol.* 2007;13:4199–206.
72. Ford ES. Body mass index and colon cancer in a national sample of adult US men and women. *Am J Epidemiol.* 1999;150:390–8.
73. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *Am J Clin Nutr.* 2007;86:556–65.
74. Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. *Int J Obes Relat Metab Disord.* 2004;28:559–67.
75. Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer.* 2006;118:728–38.
76. Wang Y, Jacobs EJ, Patel AV, Rodriguez C, McCullough ML, Thun MJ, et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. *Cancer Causes Control.* 2008;19:783–92.

77. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst.* 2006;98:920–31.
78. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst.* 2005;97:1679–87.
79. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med.* 2006;166:1871–7.
80. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA.* 2005;293:194–202.
81. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *Br J Cancer.* 2001;84:417–22.
82. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2003;12:412–8.
83. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. *J Natl Cancer Inst.* 2004;96:546–53.
84. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev.* 2005;14:850–5.
85. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. *J Cell Physiol.* 2000;183:1–9.
86. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. *Cancer Epidemiol Biomarkers Prev.* 1996;5:1013–5.
87. Tran TT, Naigamwalla D, Oprea AI, Lam L, McKeown-Eyssen G, Bruce WR, et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. *Endocrinology.* 2006;147:1830–7.
88. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. *J Nutr Biochem.* 2006;17:145–56.
89. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. *J Natl Cancer Inst.* 2002;94:972–80.
90. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA.* 2006;295:1549–55.
91. Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Wada R, Mitsushima T, et al. The effect of body weight reduction on the incidence of colorectal adenoma. *Am J Gastroenterol.* 2008;103:2061–7.
92. Rosen AB, Schneider EC. Colorectal cancer screening disparities related to obesity and gender. *J Gen Intern Med.* 2004;19:332–8.
93. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. *Am J Gastroenterol.* 2006;101:1872–9.
94. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care.* 2004;27:1047–53.
95. Flood A, Strayer L, Schairer C, Schatzkin A. Diabetes and risk of incident colorectal cancer in a prospective cohort of women. *Cancer Causes Control.* 2010;21:1277–84.
96. Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, Sandler RS. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. *Cancer Epidemiol Biomarkers Prev.* 2009;18:1239–42.
97. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. *Clin Gastroenterol Hepatol.* 2005;3:587–94.
98. Limburg PJ, Anderson KE, Johnson TW, Jacobs Jr DR, Lazovich D, Hong CP, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. *Cancer Epidemiol Biomarkers Prev.* 2005;14:133–7.

99. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. *Gastroenterology*. 2004;127:1044–50.
100. Jin T. Why diabetes patients are more prone to the development of colon cancer? *Med Hypotheses*. 2008;71:241–4.
101. Berster JM, Goke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. *Arch Physiol Biochem*. 2008;114:84–98.
102. Campbell PT, Deka A, Jacobs EJ, Newton CC, Hildebrand JS, McCullough ML, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. *Gastroenterology*. 2010;139:1138–46.
103. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst*. 1999;91:542–7.
104. Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2008;17:3108–15.
105. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. *Cancer Epidemiol Biomarkers Prev*. 2004;13:915–9.
106. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). *Cancer Causes Control*. 1999;10:379–86.
107. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. *Int J Cancer*. 2011;128:1668–75.
108. Wong RJ. Marked variations in proximal colon cancer survival by race/ethnicity within the United States. *J Clin Gastroenterol*. 2010;44:625–30.
109. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. *Cancer Biomark*. 2007;3:301–13.
110. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, et al. Race and colorectal cancer disparities: health-care utilization vs. different cancer susceptibilities. *J Natl Cancer Inst*. 2010;102:538–46.
111. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, Romero Y, et al. Colorectal cancer in African Americans. *Am J Gastroenterol*. 2005;100:515–23. discussion 514.
112. Anderson JC, Attam R, Alpern Z, Messina CR, Hubbard P, Grimson R, et al. Prevalence of colorectal neoplasia in smokers. *Am J Gastroenterol*. 2003;98:2777–83.
113. Cash B, Flood A, Weiss DG, Schatzkin A, Lieberman D, Schoenfeld P. Risk factors for advanced colorectal neoplasia in women: comparison of the CONCeRN and VA 380 populations (Abstract). *Gastroenterology*. 2006;130:A-186.
114. Lieberman DA, Prindiville S, Weiss DG, Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. *JAMA*. 2003;290:2959–67.
115. Anderson JC, Latreille M, Messina C, Alpern Z, Grimson R, Martin C, et al. Smokers as a high-risk group: data from a screening population. *J Clin Gastroenterol*. 2009;43:747–52.
116. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. *Gastroenterology*. 2008;134:388–95.
117. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. *JAMA*. 2008;300:2765–78.
118. Stein B, Anderson JC, Rajapakse R, Alpern ZA, Messina CR, Walker G. Body mass index as a predictor of colorectal neoplasia in ethnically diverse screening population. *Dig Dis Sci*. 2010;55:2945–52.
119. Anderson JC, Messina CR, Dakhllallah F, Abraham B, Alpern Z, Martin C, et al. Body mass index: a marker for significant colorectal neoplasia in a screening population. *J Clin Gastroenterol*. 2007;41:285–90.



120. Anderson JC, Alpern Z, Messina CR, Lane B, Hubbard P, Grimson R, et al. Predictors of proximal neoplasia in patients without distal adenomatous pathology. *Am J Gastroenterol*. 2004;99:472–7.
121. Anderson JC, Stein B, Kahi CJ, Rajapakse R, Walker G, Alpern Z. Association of smoking and flat adenomas: results from an asymptomatic population screened with a high-definition colonoscope. *Gastrointest Endosc*. 2010;71:1234–40.
122. Rex DK, Lieberman DA. Feasibility of colonoscopy screening: discussion of issues and recommendations regarding implementation. *Gastrointest Endosc*. 2001;54:662–7.
123. Winawer SJ. A quarter century of colorectal cancer screening: progress and prospects. *J Clin Oncol*. 2001;19:6S–12.
124. Betes M, Munoz-Navas MA, Duque JM, Angos R, Macias E, Subtil JC, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. *Am J Gastroenterol*. 2003;98:2648–54.
125. Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, et al. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. *Cancer Causes Control*. 2000;11:477–88.
126. Kim DJ, Rockhill B, Colditz GA. Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk. *J Clin Epidemiol*. 2004;57:332–40.
127. Driver JA, Gaziano JM, Gelber RP, Lee IM, Buring JE, Kurth T. Development of a risk score for colorectal cancer in men. *Am J Med*. 2007;120:257–63.
128. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. *J Clin Oncol*. 2009;27:686–93.
129. Colorectal Cancer Mortality Projections, National Cancer Institute. Bethesda, MD: NIH, DHHS, 2007.
130. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med*. 2009;150:1–8.
131. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. *J Natl Cancer Inst*. 2010;102:89–95.
132. Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH, et al. CIMP status of interval colon cancers: another piece to the puzzle. *Am J Gastroenterol*. 2010;105:1189–95.
133. Shaikat A, Arain M, Thyagarajan B, Bond JH, Sawhney M. Is BRAF mutation associated with interval colorectal cancers? *Dig Dis Sci*. 2010;55:2352–6.
134. Li D, Jin C, McCulloch C, Kakar S, Berger BM, Imperiale TF, et al. Association of large serrated polyps with synchronous advanced colorectal neoplasia. *Am J Gastroenterol*. 2009;104:695–702.
135. Anderson JC, Pleau DC, Rajan TV, Protiva P, Swede H, Brenner B, et al. Increased frequency of serrated aberrant crypt foci among smokers. *Am J Gastroenterol*. 2010;105:1648–54.
136. Anderson JC, Rangasamy P, Rustagi T, Myers M, Sanders M, Vaziri H, et al. Risk factors for sessile serrated adenomas. *J Clin Gastroenterol*. (In Press)



<http://www.springer.com/978-1-60761-397-8>

Colorectal Cancer Screening

Anderson, MD, J.; Kahi, MD, C. (Eds.)

2011, X, 205 p., Hardcover

ISBN: 978-1-60761-397-8

A product of Humana Press